Across TCGA pan-cancer cohorts, IGLV2-23 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated IGLV2-23 data layer compared with 3 for mutation status and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGLV2-23 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated IGLV2-23 expression acts as an unfavorable survival marker, although some lineages such as HNSC and SKCM show a favorable association.
HNSC, SKCM, and BRCA are the cancer types where IGLV2-23 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.